CG
INDV icon

Caprock Group’s Indivior Pharmaceuticals INDV Stock Holding History

Caprock Group’s Portfolio INDV Stock Details INDV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$266K Buy
8,727
+212
+2% +$7K 0.01% 967
2025
Q4 		$306K Buy
+8,515
New +$260K 0.01% 988

Other funds holding INDV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
OCM
Oaktree Capital Management Los Angeles, California $6.56B AUM 42.97% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Caprock Group's INDV Position: Q1 2026 in Review

Caprock Group increased its Indivior Pharmaceuticals (INDV) stake by 2.5% in Q1 2026, buying an estimated $7K and bringing the position to 8,727 shares worth $266K. The position accounts for 0.01% of the portfolio, ranked #967.

Caprock Group first reported a position in INDV in Q4 2025 and has held it in 2 quarters since. The position peaked at $306K in Q4 2025. 289 funds tracked by Wall St. Rank hold INDV as of Q1 2026.

  • Caprock Group held 8,727 shares of Indivior Pharmaceuticals worth $266K as of Q1 2026.
  • Caprock Group bought 212 Indivior Pharmaceuticals shares in Q1 2026, an estimated $7K.
  • Indivior Pharmaceuticals made up 0.01% of Caprock Group's portfolio in Q1 2026, its #967 holding.
  • Caprock Group first reported a position in Indivior Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • Caprock Group's Indivior Pharmaceuticals position peaked at $306K in Q4 2025.
  • 289 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q1 2026.

Based on Caprock Group's 13F filing for Q1 2026, filed 11 May 2026.